PHARMAC is seeking feedback on a provisional agreement to: fund azacitidine (Vidaza) 100 mg injection for patients with intermediate-2 or high risk myelodysplatic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) or MDS-associated acute myeloid leukaemia (AML); and fund lenalidomide (Revlimid) 10 and 25 mg capsules for relapsed refractory multiple myeloma (MM); and reduce the price and subsidy for thalidomide (Thalomid) 50 mg and 100mg capsules. Closes: Thursday, 10 July 2014.
PHARMAC is funding ticagrelor, a new treatment to help prevent heart attacks, from 1 July 2013.
PHARMAC is pleased to announce the approval of changes to the Special Authority criteria and Hospital Medicine List (HML) restriction for somatropin.
PHARMAC is seeking feedback on a proposal to award sole supply of erythropoietin. The proposal would also widen access to erythropoietin to include patients with myelodysplasia, and patients for whom blood transfusion is not a viable treatment option (in hospital only). Closes: 4 July 2014.
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to list ferric carboxymaltose (Ferinject) 500 mg per 10 ml vial in Section H of the Pharmaceutical Schedule from 1 July 2014 for the treatment of iron deficiency anaemia.
PHARMAC is pleased to announce decisions relating to the listing of contrast media agents that will take effect from 1 July 2014.
Decision to widen access and fund adalimumab and etanercept for the treatment of pyoderma gangrenosum
PHARMAC is pleased to announce the approval of a proposal to fund adalimumab and etanercept to treat pyoderma gangrenosum in the community and hospital setting.
PHARMAC is welcoming the appointment of two new members to the Pharmacology and Therapeutics Advisory Committee.
Significant clinical issues were raised during consultation on this proposal. The need to consider these issues and seek further advice from PTAC means we will not be progressing the melatonin proposal at this time.
PHARMAC has approved a proposal to make changes to the funding of various non-steroidal anti-inflammatory drugs.
PHARMAC is pleased to announce the approval of an agreement to fund diazoxide oral liquid 50 mg per ml, 30 ml (Proglycem Liquid) from 1 July 2014, subject to Special Authority and hospital access restrictions.
PHARMAC is pleased to announce changes to the funding access criteria for a number of vaccines.
A new brand of Amoxicillin granules for oral liquid will be listed on the Pharmaceutical Schedule from 1 July 2014. There are some differences between the new and old brands that pharmacists need to know about.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and 2013/14 Invitation to Tender, dated 07 November 2013.
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to fund melatonin 2 mg modified-release tablets (Circadin) from 1 July 2014 for secondary insomnia in children and adolescents with neurodevelopmental disorders.
PHARMAC is seeking feedback on a proposal relating to a provisional agreement for the supply of Tambocor and Tambocor CR brand of flecainide acetate and for the supply of the Qvar brand of extra fine beclometasone dipropionate aerosol inhalers. Closes: Thursday, 12 June 2014.
PHARMAC is pleased to announce the approval of an agreement with Protec Solutions Limited (“Protec”) for the supply of wound care products.
Patients with severe gout will soon have a new treatment option as PHARMAC will be funding febuxostat (Adenuric) from 1 June 2014.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.
PHARMAC is reminding clinicians and pharmacists that from 1 July 2014 the restriction applying to norfloxacin tablets in the community will be amended.